Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

A paper published in Circulation: Cardiovascular Quality and Outcomes has reported that extended-release niacin with laropiprant did not significantly reduce the risk of major vascular events and increased the risk of serious adverse events in Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), but its net effects on health and healthcare costs are unknown.

Researchers from HERC (Seamus Kent, Alastair Gray and Borislava Mihaylova) and CTSU concluded that in HPS2-THRIVE, the addition of extended-release niacin–laropiprant to statin-based therapy reduced quality of life–adjusted survival and increased hospital costs.

Link to paper: http://bit.ly/2a8QllA

Link to editorial: http://bit.ly/29vkONA

DOWNLOAD

Reliable estimates of the impacts of categories of adverse events on health and healthcare costs are needed to evaluate the net effects of health interventions. The estimates of the quality of life and cost impacts of adverse events derived from HPS2-THRIVE data are now available for use in other analyses of effects of interventions in secondary cardiovascular disease populations. To assist such efforts, see the downloadable calculator at http://www.herc.ox.ac.uk/downloads/supportingmaterial.